BlueYard Capital — 2023 Investments
3 investments dated 2023 · listed companies and verified rows first · show all
Vectary is a browser-based 3D design and collaboration platform used across the product development process from concept to market.
Creator EconomyFuture of WorkSaaSRedwood City, US
Pavol Sovis(Director)Michal Koor(Executive Officer, Director)Ted Persson(Director)
BoardCiaran OLeary(Director)
Board seatCiaran O'Leary· per SEC Form D
Co-investorsNeulogy Ventures
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue.
AI & Machine LearningBiotechDeep TechTolland, US
John Deacon(Executive Officer, Director)Colin J. Foster(Executive Officer, Director)
BoardJason Whitmire(Director)inAlex Brunicki(Director)
Co-investorsBackedBY Capital GmbH Co. KG
Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development.
AI & Machine LearningBiotechDeep TechHealthtechOxford, GB
Miroslav Gasparek(Founder)inMarian Kupculak(Founder)in
Co-investorsCivilization Ventures Management, LlcKAYARecode VenturesY CombinatorZAKA VC
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.